Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Increased Antitumor Immunity of Mouse GM-CSF in Mouse Colon Tumor (CT-26) Model

  • Received : 2013.08.05
  • Accepted : 2013.12.27
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Oncolytic vaccinia virus is an engineered vaccinia virus that selectively destroys cancer cells and induces tumor immune response. Oncolytic vaccinia expressing mouse GM-CSF showed cytotoxic activity against various kinds of cancer cells when oncolytic vaccinia virus expressing human GM-CSF and mouse GM-CSF is intravenously administered in the mouse CT26 colon tumor model. Cancer cells treated with isolated immunoglobulin G from the serum with complement showed these cytotoxic activity and complement observed dose-dependent cytotoxic effect. These results suggest that oncolytic vaccinia virus expressing mouse GM-CSF can increase oncolytic vaccinia virus by inducing anticancer antibody in a mouse tumor model. Further studies are needed on antitumor immunity of GM-CSF.

Keywords

References

  1. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 2007. 15: 1686-1693. https://doi.org/10.1038/sj.mt.6300215
  2. Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther. 1996. 69: 1-14. https://doi.org/10.1016/0163-7258(95)02016-0
  3. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000. 108: 641-652. https://doi.org/10.1046/j.1365-2141.2000.01863.x
  4. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998. 16: 444-448. https://doi.org/10.1038/nbt0598-444
  5. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002. 188: 147-154. https://doi.org/10.1034/j.1600-065X.2002.18813.x
  6. Fossati G, Mazzucchelli I, Gritti D, Ricevuti G, Edwards SW, Moulding DA, Rossi ML. In vitro effects of GM-CSF on mature peripheral blood neutrophils. Int J Mol Med. 1998. 1: 943-951.
  7. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997. 3: 639-645. https://doi.org/10.1038/nm0697-639
  8. Hermiston TW, Kirn DH. Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development. Mol Ther. 2005. 11: 496-507. https://doi.org/10.1016/j.ymthe.2004.12.004
  9. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 2002. 9: 1022-1035. https://doi.org/10.1038/sj.cgt.7700542
  10. Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008. 18: 104-111. https://doi.org/10.1097/CMR.0b013e3282f702cf
  11. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther. 2006. 14: 361-370. https://doi.org/10.1016/j.ymthe.2006.05.008
  12. Kim MK, Caroline JB, Anne M, Heo J, Lee YK, Cho M, Lee J W, Kim SG, Kang DH, John CB, Park BH, Kirn DH, Hwang TH. Oncolytic and Immunotherapeutic Vaccinia Induces Antibody- Mediated Complement-Dependent Cancer Cell Lysis in Humans. Sci Transl Med. 2013. 5: 185-163.
  13. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001. 7: 781-787. https://doi.org/10.1038/89901
  14. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009. 9: 64-71. https://doi.org/10.1038/nrc2545
  15. Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010. 17: 73-79. https://doi.org/10.1038/cgt.2009.50
  16. Lee S, Margolin K. Cytokines in Cancer Immunotherapy. Cancers. 2011. 3: 3856-3893. https://doi.org/10.3390/cancers3043856
  17. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991. 10: 854-856.
  18. Mastrangelo MJ, Maguire HC Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999. 6: 409-422. https://doi.org/10.1038/sj.cgt.7700066
  19. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005. 5: 965-976. https://doi.org/10.1038/nrc1750
  20. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 2006. 16: 182-188. https://doi.org/10.1038/sj.cr.7310025
  21. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994. 30: 1165-1171. https://doi.org/10.1016/0959-8049(94)90477-4
  22. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000. 6: 821-825. https://doi.org/10.1038/77558
  23. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr. 2008. 2: 208-213. https://doi.org/10.4161/cam.2.3.6353
  24. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001. 1: 153-161.
  25. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther. 2012. 20: 287-297. https://doi.org/10.1038/mt.2011.208
  26. Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses. J Virol. 2005. 79: 5455-5465. https://doi.org/10.1128/JVI.79.9.5455-5465.2005